What is HCC?

Harvard Cancer Consortium (HCC) is an NCI-designated comprehensive cancer center that unites the cancer research efforts of five Boston academic medical institutions—Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital—and two Harvard Schools—the Harvard Medical School and the Harvard T.H. Chan School of Public Health. 

Am I a part of HCC?

If you answered yes to both questions, then you are a part of HCC!

Do I need to submit my research to HCC?

All studies conducted under HCC must be submitted for centralized review and reporting. (This applies to all studies, whether reviewed by the DFCI IRB or an external single IRB)

Unsure whether your research project must be submitted to HCC? Review the following for guidance:

I am required to submit my research to HCC - what does that mean?

Applicable research projects are subject to HCC policies and must comply with HCC requirements, including the following:

Note - There may be additional institution-specific requirements and processes that also apply. Contact your institutional clinical trials office for guidance.